BINYAMINA, Israel and CARY,
NC, Aug. 14, 2024 /PRNewswire/ -- OncoHost, a
technology company transforming the approach to precision medicine
for improved patient outcomes, today announced that three of
its research abstracts have been selected for presentation at the
upcoming World Conference on Lung Cancer (WCLC 2024). The abstracts
highlight OncoHost's significant work in developing predictive
models for immunotherapy-related toxicities and clinical
outcomes.
The research to be presented includes one oral presentation and
two poster presentations, each showcasing the potential of plasma
proteomics in advancing personalized treatment strategies for lung
cancer patients.
Oral Presentation
Title: Plasma Proteomics-Based Models for
Predicting Immunotherapy- and Chemotherapy-Related Toxicity in
NSCLC Patients
Presenter: Prof. Jarushka Naidoo
This study addresses a critical need in the management of
metastatic non-small cell lung cancer (NSCLC) patients who are
treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs).
Prof. Naidoo will present innovative plasma proteomics-based models
designed to predict the likelihood of severe immune-related adverse
events (irAEs) and chemotherapy-related adverse events (chemo-AEs)
before treatment begins. These models offer a promising approach to
improving patient care by identifying those at higher risk of
experiencing significant toxicities, thereby allowing for more
informed treatment decisions.
"The field of immunotherapy for lung cancer has a well-developed
focus on identifying biomarkers of response and resistance to
treatment. However, biomarkers of toxicity from immunotherapy and
chemotherapy are also of clinical relevance, with the potential to
refine treatment selection and monitoring," said Jarushka Naidoo,
MD, consultant medical oncologist at Beaumont Hospital Dublin,
professor at the Royal College of Surgeons in
Ireland, and corresponding author of the study. "These data
explore the use of proteomics for this purpose and are an important
area for continued study."
Poster Presentations
Title: A Plasma Proteomics-Based Model for
Clinical Benefit Prediction in Small Cell Lung Cancer Patients
Receiving Immunotherapy
Presenter: Prof. David R.
Gandara
This research focuses on small cell lung cancer (SCLC), a
particularly aggressive form of lung cancer with limited treatment
options. Prof. Gandara will present a novel computational model
that utilizes pretreatment plasma proteomic profiles to predict
clinical outcomes for SCLC patients receiving immunotherapy (ICIs)
combined with chemotherapy. The study highlights the potential of
this model to refine treatment strategies by identifying patients
most likely to benefit from ICIs, paving the way for more
personalized and effective therapies.
"Although checkpoint immunotherapy combined with chemotherapy
has extended survival in patients with
extensive stage SCLC, many patients do not benefit, and
most patients develop recurrence. Identifying those patients most
likely to have meaningful benefit is a critical unmet need," said
David R. Gandara, MD, Division of
Hematology and Oncology, University of
California Davis Comprehensive Cancer Center, and
corresponding author of the study. "This study describes the
development of a blood-based proteomic test to
distinguish these patients at the time of diagnosis, prior to
therapy. Given the rapid progression and aggressive nature of this
malignancy, this assay has the potential to truly personalize
initial treatment plans."
Title: Deciphering Immunotherapy Resistance
Mechanisms in Metastatic NSCLC: Insights from Plasma Proteomics
Analysis
Presenter: Dr. Itamar Sela,
VP R&D, OncoHost
This study delves into the mechanisms of immunotherapy
resistance in metastatic NSCLC. Dr. Sela will present findings from
the PROphetNSCLC™ test, a plasma proteomics and machine
learning-based tool designed to assist in first-line treatment
management. The research identifies six distinct groups of
resistance-associated proteins (RAPs) linked to the immune system,
tumor, and other tissues, offering valuable insights into the
biological processes underlying resistance to immunotherapy.
"Our research showcases the groundbreaking potential of plasma
proteomics in oncology," said Yehuda
Brody, PhD, Senior Computational Biologist Researcher at
OncoHost. "By leveraging non-invasive liquid biopsy samples, we've
identified specific resistance mechanisms and biomarkers within the
plasma proteome. This approach provides a multisystem overview,
bringing us closer to truly personalized treatment strategies for
lung cancer patients. Our study marks a significant advancement in
decoding the complex, multifaceted nature of immunotherapy
resistance, ultimately aiming to improve personalized patient
treatment decisions."
OncoHost's participation in WCLC 2024 underscores its commitment
to advancing the field of oncology through innovative research and
technology. The company looks forward to sharing these important
findings with the global oncology community.
About OncoHost
OncoHost is a technology company headquartered in Binyamina,
Israel, and Cary, North Carolina, transforming the
approach to precision medicine for improved patient outcomes.
OncoHost's proprietary platform, PROphet®, is a plasma-based,
proteomic pattern analysis tool whose initial offering in non-small
cell lung cancer (NSCLC) uses a single blood sample to guide
first-line immunotherapy decision-making. The PROphetNSCLC™ test
provides clear clinical utility by offering physicians crucial
guidance on the optimal first-line immunotherapy treatment plan for
each individual patient, with a significant effect on overall
survival. Led by an experienced team of entrepreneurs and industry
experts and supported by a large-scale prospective clinical trial
with over 40 sites and 1,700 patients recruited worldwide, OncoHost
is well-positioned to lead precision diagnostics and biomarker
development to the next stage.
For more information, visit www.oncohost.com, or follow OncoHost
on LinkedIn, Twitter, Facebook and YouTube.
Media Contact:
Lior Alperovich
Marcom Manager
lior@oncohost.com
+972-54-282-4503
View original
content:https://www.prnewswire.com/news-releases/oncohost-announces-three-abstracts-selected-for-presentation-at-wclc-2024-302222641.html
SOURCE OncoHost